Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE: Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies
NCT04094610Phase 2Recruiting
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Mar 2020
- Primary completion
- Sep 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 11
01
Overview
Phase 2, open-label trial of repotrectinib in solid tumor, lymphoma and central nervous system tumor (4 arms), sponsored by Turning Point Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicities at 28 days, Pediatric Recommended Phase 2 Dose at 28 days and 1 more. Started Mar 2020; status: recruiting.
02
Drugs
repotrectinib
03
Conditions
solid tumorlymphomacentral nervous system tumor
Beyond the preview
Go deeper on NCT04094610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094610.